Blinklab Limited (AU:BB1) has released an update.
Blinklab Limited, a pioneer in digital healthcare, has released a report detailing significant strides in developing AI and smartphone-based diagnostics for neurological conditions. The company has launched several clinical studies, including partnerships with the Turning Pointe Autism Foundation and Erasmus University Medical Centre, and is advancing regulatory strategies for US and EU device registration. With a strong cash position and major software updates rolled out, Blinklab is poised to transform the diagnosis of autism, ADHD, and other neurodevelopmental disorders.
For further insights into AU:BB1 stock, check out TipRanks’ Stock Analysis page.
